Updated:
Nuvation Bio
Discover Nuvation Bio, Inc., a leader in oncology drug development. Learn about our innovative pipeline and commitment to transforming cancer treatment.
Nuvation Bio
Discover Nuvation Bio, Inc., a leader in oncology drug development. Learn about our innovative pipeline and commitment to transforming cancer treatment.
General information
Firm type
Asset Manager
Year founded
2018
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New York
Corporate office
1500 Broadway, Suite 1401, New York, NY 10036, United States
Additional offices
San Francisco, CA, United States · Burlington, MA, United States · Shanghai, China · Beijing, China · Hangzhou, China
Principals
David Hung
Founder, President, and Chief Executive Officer
Sector focus
Frequently asked questions
Who leads Nuvation Bio, and what is his track record?
David Hung founded Nuvation Bio in 2018 and serves as president and CEO. He previously founded Medivation, which developed the prostate-cancer drug enzalutamide and was acquired by Pfizer for approximately $14 billion in 2016. Hung's role at Nuvation Bio combines strategic capital allocation with direct oversight of the pipeline that targets cancers with few remaining treatment options.
Is Nuvation Bio structured as a family office or a biotech operating company?
Nuvation Bio is a publicly traded oncology company listed on the New York Stock Exchange — not a family office. It develops its own proprietary drug candidates and acquires external programs through business development. All capital deployment flows through the corporate entity, not through external limited-partner funds.
What is Nuvation Bio's investment stage and asset-class focus?
The firm operates exclusively in clinical-stage oncology, advancing small-molecule and biologic drug candidates through human trials. Nuvation Bio transitioned from pure clinical development to commercial-stage in 2025, meaning at least one product now generates revenue. The company does not invest in third-party venture funds, real estate, or non-biotech sectors.
How does Nuvation Bio access the Chinese market?
Nuvation Bio maintains three China-based offices — in Shanghai, Beijing, and Hangzhou — that support clinical trials, regulatory engagement, and operational execution. This dual-jurisdiction setup enables parallel development under both US FDA and China NMPA frameworks, a structural feature most small-cap US biotechs lack.
What was the operational milestone Nuvation Bio hit most recently?
In 2025, Nuvation Bio became a commercial-stage company, shifting its financial profile from preclinical R&D to marketed-product revenue. The firm commemorated the transition by ringing the closing bell at the New York Stock Exchange.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: